A patient walks into Cecelia Health already in trouble.
They'd gotten a GLP-1 through a direct-to-consumer site. Highest dose of Wegovy, no ramp. By the time they reached Cecelia's care team, they had severe nausea and a painful skin rash. Bad, but survivable.
Here's the part that should scare you.
That same patient had major depressive disorder and was on an SSRI. SSRIs carry an appetite-suppression effect of their own. Stack that on top of a max-dose GLP-1 and you don't have two mild side effects, you have a patient heading toward dehydration, malnutrition, and an ER bill. The prescriber never caught it, because the intake never asked. They didn't have the medical history. They weren't a medical practice. They were a checkout flow.
Cecelia's team stepped the patient down to a lower dose. The patient stabilized. No ER visit.
That story is the whole thesis of this episode, and it's why we wanted Mark Clermont and Wendi Mader from Cecelia Health on the show. The tools are getting better and healthcare is somehow getting more fragmented at the same time. Understanding why is one of the most useful things an operator can do right now.
Who's on the mic
Mark Clermont runs Cecelia Health. He joined in January 2021, back when the company was running a clinical study, backed by the Helmsley Charitable Trust, to prove something that sounds obvious in 2026 and was heresy then: that diabetes could be managed virtually. To do it, they built a medical practice licensed in all 50 states.
Wendi Mader is the commercial leader. Twenty-plus years in healthcare that started, of all places, with her going anemic as a college athlete and realizing she couldn't run her mile time. That sent her down the preventive-care path and eventually deep into the clinical side.
What Cecelia is today: a multi-specialty virtual medical practice. A network of RNs, RDs, and certified diabetes care and education specialists, with physicians behind the scenes, managing chronic and cardiometabolic disease. Not a wellness app. A practice that prescribes, titrates, and coordinates.
We're an extension of primary care.
That distinction is the entire business.
The point-solution trap
Wendi says the same sentence in every commercial conversation:
We're not a point solution. We're a specialty virtual medical practice, and we practice medicine.
The reason she has to keep saying it: the last decade of wellness taught buyers to think in point solutions. One vendor for the pre-diabetics. Another for the diabetics. A separate program for the type 1s. Health coaches over here, the actual clinical stuff over there. Everybody optimizing their slice, nobody holding the patient.
Her example lands hard. Half of dialysis patients are diabetic. Many of them have no endocrinologist at all. So the nephrologist keeping them alive on dialysis looks at the diabetes and, reasonably, says that's not my job. The gap just sits there.
That's the population a point solution can't touch, because a point solution can't see the whole person. And these are exactly the high-cost claimants every self-insured employer is losing sleep over.
Until the squeaky wheel starts squeaking, we don't do anything about it. And so we've got to wrap our arms around that patient as a healthcare system.
The takeaway for anyone selling into healthcare: "point solution" has quietly become a liability label. The market is done paying for another disconnected feature.
The first drug class that doesn't respect specialty lines
Mark's big insight is one we hadn't heard framed this cleanly:
It's the first drug class that has indications that cross medical specialties.
Walk the list. GLP-1s treat diabetes, which lives in endocrinology. They got an indication for obstructive sleep apnea, which lives in pulmonology and sleep medicine. They're used for fatty liver disease, which is hepatology. There's a growing body of evidence pointing at addiction, and Mark raised the obvious next question: what happens when there's an indication for alcoholism?
One molecule, and suddenly five specialists have a reason to prescribe it. Except in the current system, none of them are talking to each other.
Mark's model for this is worth stealing. He describes the drug indications expanding horizontally across specialties, while complementary drugs (muscle-sparing agents, the exploding GLP-1 pipeline) add a vertical view down the patient journey. You get an ecosystem that's expanding in two directions at once and fragmenting the entire time.
His conclusion:
Multi-specialty platforms like Cecelia will become this organizing layer.
That's the bet. Not another specialty. The connective tissue between all of them.
Where the tech hype breaks
We asked both of them where the industry is over-indexing on AI. Neither gave the "AI fixes everything" answer, and neither gave the cynical one.
Wendi's read: the near-term win is making clinicians more efficient, not replacing them. Ambient documentation, note generation, pharmacogenomics to match a patient to the right GLP-1. Real leverage against a real specialist shortage. Where it's gone wrong is the consumer side, where people are self-guiding more than they should.
She made it personal:
I'm from the state of Iowa and I'm watching my parents age and the healthcare practitioners there have all retired or left.
That's the actual crisis AI should be pointed at. Healthcare deserts, not chatbots.
Mark drew the sharpest line of the conversation. Cecelia uses AI for documentation and is deliberately slow to let it near clinical decisions:
We are going to be very circumspect about where that starts to intersect into clinical decisioning.
His reason is the one everyone building AI in a regulated space should tattoo somewhere:
What there is a lack of is a body of evidence, real clinical medical evidence, and the quality of evidence to support clinical decisioning.
The drug pipeline is moving faster than the evidence base. When your ground truth is thin, you do not hand the wheel to a model. You point the model at the paperwork and keep the clinician on the decision.
What "working" looks like in five years
We closed by asking Mark what actually changes for patients if Cecelia wins.
His answer wasn't about the company. It was about a hybrid system where care is coordinated whether you're at home, in a clinic, or on your phone, and where the right information shows up at the right time.
Not just you as a patient, of course, but also your clinical decisioning team has the right information at the right time.
Then he undercut his own timeline, which is why we trust him:
Healthcare in the US, evolution in the US moves very slowly. So five years may be a bit of a pipe dream.
There's a tailwind, though. New models like Access and Elevate, obesity coverage coming to Medicare in 2027, and roughly $50 billion in federal funding aimed at rural health and chronic condition management. The incentives are finally starting to point upstream, toward prevention, after decades of paying only for the episode.
Four things we're taking from this
Fragmentation is a coordination problem wearing a clinical costume. The GLP-1 patient didn't need better medicine. They needed one team that could see the SSRI and the max-dose GLP-1 at the same time. Whoever owns the organizing layer owns the outcome.
"Point solution" is now a positioning risk. If you sell into healthcare, get out of the feature category and into the practice-or-infrastructure category. Wendi repeats her line for a reason. Buyers are fatigued and they're screening for it.
When a product's indications cross buyer lines, that's the whole opportunity. GLP-1s went from one specialty to five. Watch for the same pattern in your own market. The value isn't in any single lane, it's in being the thing that connects the lanes nobody else will.
In regulated verticals, AI's first ROI is the workflow, not the decision. Documentation, note-taking, matching. Real value, low risk. The decision layer waits for the evidence, and right now the evidence is losing the race to the pipeline. Mark's "circumspect" is a feature, not timidity.
The wedge underneath all of it is cost plus safety. High-cost claimants and avoided ER visits. That's the language the buyer speaks. Lead there, not with wellness.
Thanks to Mark Clermont and Wendi Mader for the conversation. If you're building at the intersection of chronic care, GLP-1s, and coordination, this is the one to forward.
Episode 535 is presented by Sage Growth Partners - "Value-focused strategy and marketing for growth-driven healthcare organizations."
